CMPS Stock — COMPASS Pathways Plc: Cash, EV, Pipeline

What they do

We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments.

Source: 10-K FY2025 via SEC EDGAR

Share price

$8.61

Market cap

$1,220.1M

Cash

$444.0M

Enterprise value

$827.1M

Balance sheet

Cash	$444.0M
Debt	$51.0M
Net cash	$393.0M
Enterprise value	$827.1M
Basic shares	141.7M shares
Fully diluted shares	185.6M shares
Fully diluted market cap	$1,598.4M
Cash per share	$3.13
Quarterly burn	$40.3M
Cash runway	10.8 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

138.5M

Pre-funded warrants

23.8M

Options

9.9M

RSUs

1.5M

Warrants

11.9M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

185.6M

Cap table as of 2026-07-30.

Price history

Loading CMPS daily closes…

Loading price history…

Next catalyst

COMP360 · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

Psilocybin Phase 3 Positive · 2026-09-09

Source release →

COMP360 (psilocybin) Phase 3 Positive · 2026-07-07

COMP006 Part B · treatment-resistant depression

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	COMP360 NDA final submission	Not disclosed	final	Q4 2026
Dec 13, 2028 - Jan 24, 2029 in 26 mo	COMP360 psilocybin	Phase 2/3	PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

COMP360

Phase 3 · Active Modality: psilocybin therapy

Target 5-HT2A

Indications

treatment-resistant depression (TRD) (Phase 3)
post-traumatic stress disorder (PTSD) (Phase 2/3)

Status note Single asset company (non-COMP360 preclinical/discovery work stopped Q4 2024). TRD: two pivotal trials (COMP005 single 25mg; COMP006 repeat-dose); Part B COMP006 results announced July 2026; rolling NDA submission in preparation (no submission date stated). PTSD: open-label Phase 2 completed; Phase 2b/3 trial planned. FDA Breakthrough Therapy designation (2018) for TRD.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Psilocybin
Lead indication	Treatment Resistant Depression
Lead phase	Phase 3
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05711940	Phase 3	Active, not recruiting	Sponsor	COMPASS Pathways	—	Treatment Resistant Depression	—
NCT07570654	Phase 2/3	Recruiting	Sponsor	COMPASS Pathways	—	PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms	—
NCT05733546	Phase 2	Active, not recruiting	Sponsor	COMPASS Pathways	—	Major Depressive Disorder	—
NCT06247839	Phase 3	Recruiting	Collaborator	Sharmin Ghaznavi	—	Major Depressive Disorder	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for COMPASS Pathways on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	10,700,974	+68,584	1.29%	2026-08-14
Tang Capital Partners	5,000,000	+997,800	3.21%	2026-08-14
Logos Global Management	2,250,000	+2,250,000	1.37%	2026-08-14
DAFNA Capital	2,011,952	-406,930	5.43%	2026-08-14
Aisling Capital	1,432,336	no change	4.30%	2026-08-13
Ikarian Capital	15,000	-660,000	0.03%	2026-08-14
Baker Bros. Advisors	0	-2,344,720	0.00%	2026-08-14
OrbiMed Advisors	0	-1,150,646	0.00%	2026-08-14
Vivo Capital	0	-200,000	0.00%	2026-08-14
Ally Bridge Group	0	-1,045,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CMPS — COMPASS Pathways Plc ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CMPS — COMPASS Pathways Plc